<scp><i>Limosilactobacillus reuteri</i> RE225</scp> alleviates gout by modulating the <scp>TLR4</scp>/<scp>MyD88</scp>/<scp>NF</scp>‐<scp><i>κ</i>B</scp> inflammatory pathway and the Nrf2/<scp>HO</scp>‐1 oxidative stress pathway, and by regulating gu
This study provides a theoretical basis for the comprehensive development of Limosilactobacillus reuteri and new ideas for the non-pharmacological treatment of gout. © 2024 Society of Chemical Industry.
Authors
- Xiurong Su (ORCID: https://orcid.org/0000-0003-2336-191X)
- Jun Zhou (ORCID: https://orcid.org/0000-0003-0346-1390)
- Qin Yang (ORCID: https://orcid.org/0000-0002-9792-4431)
- Jiayi Xiong
- Chenyang Lu (ORCID: https://orcid.org/0000-0001-9128-6769)
- Jiaojiao Han (ORCID: https://orcid.org/0000-0003-2821-8522)
- Yucong Zhou
Institutions
- Ningbo University (CN)
- Zhejiang Wanli University (CN)
Publication Details
- Journal
- Journal of the Science of Food and Agriculture
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/jsfa.13908
- Citations
- 11
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 3.73